TREM1 antibody

Catalog No. ABIN2192226

Product Details anti-TREM1 Antibody

Target: TREM1 (Triggering Receptor Expressed On Myeloid Cells 1 (TREM1))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TREM1 antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Functional Studies (Func), Immunoassay (IA)

Sterility: 0.2 μm filtered

Clone: 6B1

Application Details

Application Notes: It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting. Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one

Restrictions: For Research Use only

Handling

Buffer: PBS, containing 0.1 % bovine serum albumin.

Storage: 4 °C

Storage Comment: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

Expiry Date: 12 months

References for anti-TREM1 antibody (ABIN2192226)

Radsak, Taube, Haselmayer, Tenzer, Salih, Wiewrodt, Buhl, Schild: "Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease." in: Clinical & developmental immunology, Vol. 2007, pp. 52040, (2008) (PubMed).

Haselmayer, Grosse-Hovest, von Landenberg, Schild, Radsak: "TREM-1 ligand expression on platelets enhances neutrophil activation." in: Blood, Vol. 110, Issue 3, pp. 1029-35, (2007) (PubMed).

Target Details for TREM1

Target: TREM1 (Triggering Receptor Expressed On Myeloid Cells 1 (TREM1))

Alternative Name: Triggering Receptor Expressed On Myeloid Cells 1 (TREM1 Products)

Background: (TREM-1). TREM-1 is a transmembrane glycoprotein belonging to a family related to the natural killer cell receptors. TREM-1 is an important activating receptor, of 26 kDa, involved in the innate inflammatory response and in sepsis. TREM-1 is expressed at low levels in the early development of the hematopoietic system and in the promonoistic stage and at high levels on neutrophil granulocytes (PMN), monocytes, and macrophage subsets. The expression of TREM-1 is upregulated by microbial products, that is, by toll-like receptor ligands such as lipoteichoic acid (LTA) of Gram-positive or lipopolysaccharide (LPS) of Gram-negative bacteria. Ligation of TREM-1 is synergistic with TLR agonists on the activation of receptor bearing cells. Platelets express a natural ligand for TREM-1. Receptor ligation activates the full repertoire of effector functions. TREM-1 is also produced in a soluble form (sTREM-1) of 17 kDa which is released in humans after endotoxin exposition or in patients suffering from severe pneumonia or sepsis. sTREM-1 can be measured in biological fluids and may be useful as a diagnostic tool. The monoclonal antibody 6B1 recognizes both membrane bound and soluble TREM-1. Also, the monoclonal antibody 6B1 neutralizes the interaction between TREM-1 and its ligand. TREM-1, triggering receptor expressed on myeloid cells 1, TREM1 Aliases Recombinant TREM-1 - IgG1 fusion protein. Immunogen Mouse IgG1